Nefazodone

Strong CYP3A4 inhibitor causing significant increases in colchicine plasma levels.

Anticipated significant increase in saxagliptin plasma concentrations. Do not coadminister with dapagliflozin and saxagliptin.

Strong CYP3A4 inhibitor that increases simvastatin plasma levels, elevating risk of myopathy and rhabdomyolysis.

Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.

Strong CYP3A4 inhibitor may increase systemic corticosteroid effects of fluticasone propionate.

Strong CYP3A4 inhibitor may increase systemic corticosteroid and cardiovascular adverse effects when used with fluticasone propionate and salmeterol.

CYP3A4 inhibitor may increase systemic exposure to irinotecan or SN-38. Do not administer unless no therapeutic alternatives.

Strong CYP3A4 inhibitor that increases ivabradine plasma concentrations, exacerbating bradycardia and conduction disturbances.

Strong CYP3A4 inhibitor increases risk of myopathy by reducing lovastatin elimination.

Strong CYP 3A4 inhibitor; should not be co-administered due to risk of vasospasm leading to cerebral ischemia and/or ischemia of extremities.

Strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids including vasospasm leading to cerebral ischemia and ischemia of extremities.

Strong CYP3A inhibitor. Do not use with ranolazine extended-release tablets.

Strong CYP3A4 inhibitor that increases simvastatin exposure and risk of myopathy and rhabdomyolysis. Concomitant use is contraindicated.

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Strong CYP3A inhibitor that substantially increases ticagrelor exposure, increasing risk of dyspnea, bleeding, and other adverse events.

Triazolam is contraindicated with nefazodone due to CYP 3A inhibition affecting triazolam metabolism.

Strong CYP3A4 inhibitor that may increase DM1 exposure and toxicity. Concomitant use should be avoided or KADCYLA treatment delayed.

Strong CYP3A4 inhibitor significantly increases aprepitant exposure, increasing risk of adverse reactions. Avoid concomitant use.

Strong CYP3A inhibitor may increase plasma concentrations of cabazitaxel. Avoid coadministration or consider 25% dose reduction.

Darifenacin systemic exposure is increased with potent CYP3A4 inhibitors; daily dose should not exceed 7.5 mg when co-administered with nefazodone.

Strong CYP3A4 inhibitor increases erlotinib exposure, raising risk of exposure-related toxicity. Avoid co-administration or reduce erlotinib dosage if unavoidable.

Strong CYP3A4 inhibitor that increases erlotinib exposure and risk of exposure-related toxicity. Avoid co-administration or reduce erlotinib dosage if unavoidable.

Strong CYP3A4 inhibitor expected to increase eszopiclone exposure and effects similarly to ketoconazole. Dose reduction needed.

Strong CYP3A4 inhibitor may cause increased plasma concentration of triamcinolone acetonide and adverse reactions.

Strong CYP3A4 inhibitor may increase plasma concentration of triamcinolone leading to adverse reactions.

Strong CYP3A inhibitor may increase mifepristone plasma concentrations; limit mifepristone dose to 900 mg per day when used together.

CYP3A inhibitor that may increase nifedipine exposure. Careful monitoring and dose adjustment necessary; consider lowest dose.

Strong CYP3A4 inhibitor that significantly increases nimodipine plasma concentration and blood pressure lowering effect. Concomitant administration should generally be avoided.

Strong CYP3A inhibitor. Avoid concomitant use or reduce palbociclib dose if unavoidable.

Strong CYP3A inhibitor increases paricalcitol exposure. Dose adjustment may be necessary; monitor intact PTH and serum calcium closely.

CYP3A4 inhibitor increases quetiapine exposure; dose reduction of quetiapine necessary.

Potent CYP3A4 inhibitor that increases quetiapine exposure; dose adjustment necessary.

Strong CYP3A4 inhibitor that increases regorafenib plasma concentrations and may lead to increased toxicity.

Strong CYP3A4 inhibitor may increase salmeterol exposure and risk of cardiovascular effects.

Strong CYP3A4/5 inhibitor anticipated to significantly increase saxagliptin plasma concentrations. Limit saxagliptin dosage to 2.5 mg.

Strong CYP3A4/5 inhibitor anticipated to significantly increase saxagliptin plasma concentrations. Dose limitation required.

May increase tacrolimus whole blood trough concentrations and increase risk of serious adverse reactions including neurotoxicity and QT prolongation. Reduce tacrolimus dose and adjust based on monitoring.

Strong CYP3A4 inhibitor that increases toremifene steady-state concentration and should be avoided.

Strong CYP3A inhibitor. Avoid concomitant use with trabectedin or time administration carefully if short-term use necessary.

Strong CYP3A4 inhibitor may increase triamcinolone plasma concentration and adverse reactions.

Strong CYP3A4 inhibitor may increase systemic exposure to budesonide and cause systemic corticosteroid effects. Use with caution.

Moderate CYP3A inhibitor may increase alprazolam concentrations; avoid use or consider dose reduction.

Moderate CYP3A inhibitor may increase alprazolam concentrations. Avoid use and consider dose reduction.

Strong CYP3A4 inhibitor that may increase systemic exposure to budesonide. Use with caution.

Strong CYP3A4 inhibitor may increase systemic exposure to budesonide and increase systemic corticosteroid effects. Use with caution.

Strong CYP3A4 inhibitor that may inhibit metabolism and increase systemic exposure to budesonide. Use with caution.

CYP3A4 inhibitor that may increase buspirone concentrations; use with caution.

CYP3A4 inhibitor that may increase buspirone concentrations; concomitant use should be approached with caution.

Strong CYP3A4 inhibitor. Avoid concomitant use or reduce COMETRIQ dosage if unavoidable.

CYP3A4 inhibitor may alter serum levels of calcifediol by inhibiting vitamin D metabolism enzymes. Dose adjustment and monitoring of serum 25-hydroxyvitamin D, PTH, and calcium may be required.

CYP3A4 inhibitor that increases plasma levels of carbamazepine; dose adjustment and/or plasma level monitoring may be necessary.

Increases cyclosporine concentrations via CYP3A4 inhibition. Dosage adjustment essential.

Potent CYP3A4 inhibitor; darifenacin daily dose should not exceed 7.5 mg when co-administered.

Increases digoxin serum concentration by 27% and AUC by 15%. Requires monitoring and dose adjustment.

Moderate CYP3A4 inhibitor; administer with caution due to potential vasospasm risk.

Strong CYP 3A4 inhibitor; caution should be exercised when concomitantly administering with doxazosin mesylate.

Significant CYP3A inhibitor; estazolam should be used with caution and appropriate dosage reduction may be needed.

Strong CYP3A4 inhibitor may increase systemic corticosteroid effects by inhibiting budesonide metabolism. Use with caution.

CYP3A4 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

CYP3A4 inhibitor that increases haloperidol plasma concentrations, raising risk of adverse events including QTc prolongation.

Strong CYP3A inhibitor may increase mirtazapine plasma concentration. May require dose decrease.

Strong CYP3A4 inhibitor may increase systemic exposure to mometasone and risk of systemic corticosteroid side effects; caution advised and monitoring recommended.

Strong CYP3A4 inhibitor that may increase systemic corticosteroid effects of mometasone furoate. Use with caution and monitor for systemic corticosteroid side effects.

Strong CYP3A4 inhibitor may increase systemic exposure to mometasone furoate and increase risk of systemic corticosteroid effects. Use with caution.

Strong CYP3A4 inhibitor may increase systemic exposure to mometasone furoate and increase risk for systemic corticosteroid side effects. Caution and monitoring recommended.

CYP3A4 inhibitor; caution should be exercised when administering paclitaxel concomitantly.

Strong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse reactions, especially during first week of administration.